Rodler, S.; Aydogdu, C.; Brinkmann, I.; Berg, E.; Kopliku, R.; Götz, M.; Ivanova, T.; Tamalunas, A.; Schulz, G.B.; Heinemann, V.;
et al. Toxicity-Induced Discontinuation of Immune Checkpoint Inhibitors in Metastatic Urothelial Cancer: 6-Year Experience from a Specialized Uro-Oncology Center. Cancers 2024, 16, 2246.
https://doi.org/10.3390/cancers16122246
AMA Style
Rodler S, Aydogdu C, Brinkmann I, Berg E, Kopliku R, Götz M, Ivanova T, Tamalunas A, Schulz GB, Heinemann V,
et al. Toxicity-Induced Discontinuation of Immune Checkpoint Inhibitors in Metastatic Urothelial Cancer: 6-Year Experience from a Specialized Uro-Oncology Center. Cancers. 2024; 16(12):2246.
https://doi.org/10.3390/cancers16122246
Chicago/Turabian Style
Rodler, Severin, Can Aydogdu, Isabel Brinkmann, Elena Berg, Rega Kopliku, Melanie Götz, Troya Ivanova, Alexander Tamalunas, Gerald B. Schulz, Volker Heinemann,
and et al. 2024. "Toxicity-Induced Discontinuation of Immune Checkpoint Inhibitors in Metastatic Urothelial Cancer: 6-Year Experience from a Specialized Uro-Oncology Center" Cancers 16, no. 12: 2246.
https://doi.org/10.3390/cancers16122246
APA Style
Rodler, S., Aydogdu, C., Brinkmann, I., Berg, E., Kopliku, R., Götz, M., Ivanova, T., Tamalunas, A., Schulz, G. B., Heinemann, V., Stief, C. G., & Casuscelli, J.
(2024). Toxicity-Induced Discontinuation of Immune Checkpoint Inhibitors in Metastatic Urothelial Cancer: 6-Year Experience from a Specialized Uro-Oncology Center. Cancers, 16(12), 2246.
https://doi.org/10.3390/cancers16122246
